21SEP

Ten raises took 75.2% of life sciences

2 min read

16:52UTC

The BioIndustry Association found that ten companies absorbed 75.2% of the £2.83 billion deployed into UK life sciences in the first half of 2026, leaving a median round of £600,000.

← Back to Nscale takes $103.4bn of contracts to NYSE Jump to analysis ↓

TechnologyDeveloping

Key takeaway

Ten companies took three quarters of the money while the median British life-sciences round reached £600,000.

The ten largest life-sciences raises took 75.2% of the £2.83 billion deployed into the sector in the first half of 2026, the BioIndustry Association (BIA), the trade body for British life sciences, reported on 10 September in a study written with the accountancy firm Frazier & Deeter ¹. The median round across the same population came in at £600,000. The mean came in at £8.8 million.

A mean roughly fifteen times the median describes a market with a thin middle: a few enormous raises at the top, a long tail of very small ones, and little in between. The typical British life-sciences company raised enough to run one experiment. The British Business Bank measured the same concentration across the whole equity market last year, when artificial intelligence companies took a record 44% of smaller-business equity value . That market had a fashionable sector to explain it. This one does not, which points at round size rather than subject matter as the driver.

Go further down and the numbers shrink again. The Financial Conduct Authority (the FCA, the UK financial Conduct regulator) published feedback statement FS26/2 on 17 September, a review scoped to business lending of £25,000 or less to sole traders and small partnerships, the only small-business lending inside its consumer-credit perimeter. Within that perimeter it found that 60% of small businesses seeking finance in the past three years sought less than that ceiling ². The median life-sciences round runs twenty-four times higher, and still sits on the same floor of British business finance that most companies stand on.

Deep Analysis

In plain English

The BioIndustry Association and the accountancy firm Frazier & Deeter looked at how £2.83bn of investment into British biotechnology and life sciences companies was shared out in the first half of 2026. Most of it went to a small number of companies. The ten biggest deals took three-quarters of all the money. Meanwhile, the typical company that raised money got only £0.6m, a small amount for biotech, where clinical trials are expensive. The gap between the typical deal and the average deal shows money is going to a few big winners rather than being spread evenly.

Deep Analysis

Root Causes

A £0.6m median round against an £8.8m mean is itself the signature of a barbell market: many small cheques at one end, a handful of large ones pulling the average far above the middle. That shape follows the retrenchment of generalist crossover investors from biotech after the 2022 downturn, which left fewer funds able or willing to write the mid-sized Series B and C cheques that used to sit between seed and late-stage rounds.

With that middle thinned out, the capital that remains concentrates in a small number of larger, more de-risked late-stage deals, which is exactly what the ten largest raises taking 75.2% of the £2.83bn total describes.

What could happen next?

Risk
Companies raising near the GBP0.6m median face a harder path to the funding needed for clinical development, increasing the risk that promising early-stage UK life sciences work stalls before it reaches a fundable inflection point.

Sources:BioIndustry Association and Frazier & Deeter

Mentions:BioIndustry Association →Frazier & Deeter →British Business Bank →Conduct →Financial Conduct Authority →

First Reported In

Update #15 · Nscale takes $103.4bn of contracts to NYSE

BioIndustry Association and Frazier & Deeter· 21 Sept 2026

Read original →

Causes and effects

Caused by

AI takes record 44% of UK equity market

The life-sciences concentration mirrors the British Business Bank's finding that AI took 44% of smaller-business equity value last year.

Occurred 1 Jul 2026

Read story →

This Event

Ten raises took 75.2% of life sciences

A median round of £600,000 funds one experiment rather than a programme, and the gap to the mean shows a market with almost nothing in the middle.

Different Perspectives

Nscale and Open Cosmos

Nscale chose the New York Stock Exchange for its listing on 18 September, putting Britain's largest AI infrastructure bet to American public investors rather than British ones. Open Cosmos took the opposite route four days earlier, raising nine figures from an all-domestic syndicate on five years of profit, evidence that staying is possible when the balance sheet allows it.

Dame Chi Onwurah and the Science, Innovation and Technology Committee

Committee chair Dame Chi Onwurah wrote to government on 7 September asking how Matt Clifford's conflict at ARIA arose and what safeguards protect its governance, and expects a detailed response. Her question has not yet been put to the Sovereign AI Unit, whose own chair sits at a venture capital firm while overseeing state AI equity.

The Entrepreneurs Network

The Entrepreneurs Network's founder survey found 65% say Britain is easy to start a business in but only 14% say it is easy to scale one, with 82% negative on tax and 74% finding investment hard to access. On this reading the constraint is regulation and tax, not the capital-vehicle design the state keeps adjusting.

New Economics Foundation

The New Economics Foundation argues fiscal accounting rules, not political will, cap what Britain's state capital vehicles can do. Matching the KfW and Bpifrance benchmark of 1% of GDP would need the National Wealth Fund to deploy roughly GBP21bn a year by 2028-29, about four times its current capacity.

Competition and Markets Authority

The CMA's 8 September report on public procurement asked whether Britain's roughly GBP400bn state-spending system is built to grow high-potential firms rather than simply widen SME participation. Its Recommendation 5 calls for a dedicated frontier-technology procurement framework, an official acknowledgement that today's design may serve the wrong target.

Highland Europe

Highland Europe, the growth-equity firm behind a €1bn-plus fund, took €65m from the British Business Bank into its Technology Growth Fund VI on 30 July via British Patient Capital. For a Geneva-based growth investor, the Bank's cheque is routine cornerstone capital, unrelated to which Whitehall department currently claims to sponsor UKRI.